CSF1R and melanoma: A phase 1/1b study evaluating APX005M in combination with cabiralizumab (CSF-1R inhibitor) with or without nivolumab in NSCLC, melanoma, and RCC patients that previously have failed to respond to anti-PD-1/PD-L1 therapy (NCT03502330) is ongoing.